Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in mucosal immunomodulatory adjuvants.

Ali M Harandi1, Joaquin Sanchez, Kristina Eriksson

  • 1Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute (GUVAX), Göteborg University, Guldhedsgatan 10A, 413 46 Göteborg, Sweden. ali.harandi@microbio.gu.se

Current Opinion in Investigational Drugs (London, England : 2000)
|April 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Blood neoplasia·2026
Same author

Comparison of physical, mechanical and biological properties of a porcine urinary bladder acellular matrix collagen membrane with six other collagen membranes of animal origin.

BMC oral health·2026
Same author

Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultation.

Vaccine·2026
Same author

Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Frontiers in immunology·2026
Same author

Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Frontiers in immunology·2026
Same author

Exploring miRNAs in Leishmania infection: from immune modulation to theranostic potential.

Microbial pathogenesis·2026

New mucosal immunomodulators and adjuvants, including detoxified toxins and Toll-like receptor ligands, show promise for enhancing vaccine-induced immune responses against mucosal pathogens.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Pathogens frequently target mucosal surfaces, necessitating effective vaccines.
  • Current mucosal vaccines often lack immunostimulatory properties, leading to weak immune responses.
  • There is a significant need for agents that can modulate mucosal immunity and act as adjuvants.

Purpose of the Study:

  • To review recent advancements in mucosal immunomodulators and adjuvants.
  • To highlight novel agents for enhancing mucosal vaccine efficacy.

Main Methods:

  • Review of recent scientific literature on mucosal immunomodulators and adjuvants.
  • Focus on detoxified cholera toxin and Escherichia coli heat labile enterotoxin derivatives.
  • Emphasis on Toll-like receptor ligands such as CpG DNA and imidazoquinoline compounds.

Related Experiment Videos

Main Results:

  • Detoxified toxin derivatives and Toll-like receptor ligands show potential as mucosal adjuvants.
  • These agents can activate the innate immune system effectively.
  • They facilitate the development of strong, specific acquired immunity.

Conclusions:

  • Novel mucosal immunomodulators and adjuvants offer promising strategies for vaccine development.
  • These agents can overcome limitations of current mucosal vaccines by boosting immune responses.
  • Further research into these compounds could lead to improved protection against mucosal pathogens.